This company has been marked as potentially delisted and may not be actively trading. Bioblast Pharma (ORPN) News Today Add Compare Share Share Headlines Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock ORPN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Positive Outlook on BridgeBio Pharma’s BBP-812 Gene Therapy: Buy Rating ReaffirmedOctober 25, 2024 | markets.businessinsider.comPromising Outlook and Strategic Growth Support Buy Rating for Catalyst PharmaOctober 19, 2024 | markets.businessinsider.comPositive Developments and Potential Upside for BridgeBio Pharma: An Overweight Rating on Acoramidis Approval Prospects and Pipeline CatalystsOctober 18, 2024 | markets.businessinsider.com'Biopharma Crescent' sees rapid expansion fueled by recent investmentsOctober 12, 2024 | msn.comBuy Rating Affirmed on Urogen Pharma’s Promising Pipeline and Market Expansion PotentialOctober 4, 2024 | markets.businessinsider.comPharmaceutical giant partners with biotech company to produce animal-free protein for global nutrition: 'A win-win combination'September 27, 2024 | msn.comA weight loss drug developer's stock soars after a $198 million IPOSeptember 26, 2024 | msn.comA weight loss drug maker is aiming for a big IPOSeptember 25, 2024 | msn.comRoche Narrows Pharma Pipeline Amid Push Into Obesity MarketSeptember 24, 2024 | msn.comBioMarin Pharmaceutical: A Volatile But Growing TrajectorySeptember 17, 2024 | seekingalpha.comBridgeBio Pharma Stops Development Of BBP-631 For Congenital Adrenal HyperplasiaSeptember 11, 2024 | nasdaq.comBioMarin Pharmaceutical: Hold Rating Amidst Growth Potential and Competitive ChallengesSeptember 9, 2024 | markets.businessinsider.comBioMarin Pharmaceutical: A Buy Rating Based on Strong Growth and Operational Efficiency StrategySeptember 6, 2024 | markets.businessinsider.comBlast at Indian pharma factory kills 15 and injures 40, official saysAugust 23, 2024 | msn.comBridgeBio Pharma: Positioned for Growth with Acoramidis’ Market Potential and Positive Outlook amidst Stabilized ExpectationsAugust 22, 2024 | markets.businessinsider.comRobust Financials and Promising Clinical Trials Bolster Xenon Pharma’s Buy RatingAugust 9, 2024 | markets.businessinsider.comBalanced Outlook: BioMarin Pharmaceutical’s Strong Q2 Performance Amid Long-Term UncertaintiesAugust 7, 2024 | markets.businessinsider.comBarclays Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)August 6, 2024 | markets.businessinsider.comBioMarin Pharma to Focus Roctavian Distribution in Push for ProfitabilityAugust 6, 2024 | marketwatch.comBuy Rating Affirmed for BridgeBio Pharma on Strong Program Prospects and Competitive EdgeMay 16, 2024 | markets.businessinsider.comResearchers discover new family of bacteria with high pharmaceutical potentialMay 16, 2024 | msn.comPromising Sales Growth and Strong Clinical Prospects Underpin Buy Rating for Urogen PharmaMay 13, 2024 | markets.businessinsider.comUmbrella Labs Elevates Biotechnological Frontiers with Launch of ALPHA MSH PEPTIDE 10MG VIALApril 23, 2024 | msn.comEssential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastomaApril 10, 2024 | markets.businessinsider.comAnaptysBio Inc.March 14, 2024 | barrons.comWhat's Going On With Rare/Orphan Disease Focused-Biodexa Pharmaceuticals Stock Friday?February 23, 2024 | msn.comLantern Pharma Inc Ordinary Shares LTRNFebruary 23, 2024 | morningstar.comMQBiotics wins FDA orphan status for rainforest-derived cancer drugFebruary 18, 2024 | msn.comPBSV Pharma-Bio Serv, Inc.February 18, 2024 | seekingalpha.comAnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic SclerosisFebruary 5, 2024 | markets.businessinsider.comLumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical OfficerJanuary 4, 2024 | markets.businessinsider.comPlus Therapeutics Shares Jump Premarket on FDA Orphan DesignationNovember 3, 2023 | marketwatch.comChangzhou Qianhong Bio-Pharma Co. Ltd. AMarch 31, 2023 | wsj.com2023 Spinal Muscular Atrophy Medicine Market Report has the Potential to Deliver Genuine Review for DevelopmentMarch 1, 2023 | marketwatch.comSpinal Muscular Atrophy Medicine Market Size Global Research Report, 2023 - 2028February 18, 2023 | marketwatch.comSpinal Muscular Atrophy Medicine Market 2023 | Size, Growth Rate, Key Players Share, And Industry Trends Analysis with Global Forecast 2023-2028February 15, 2023 | marketwatch.comBioBlast Scant Data Links Drug to Improved Swallowing in PatientsFebruary 13, 2023 | thestreet.comBioMarin: Opportunity To Score Home Run With Latest Regulatory AdvancementsJanuary 30, 2023 | seekingalpha.comSpinal Muscular Atrophy Medicine Market 2023 : Research Report, Industry Growth, Competitors Analysis and Forecast 2028January 18, 2023 | marketwatch.comOrphan Drugs Market Size to Hit USD 340.84 Billion by 2027October 16, 2022 | finance.yahoo.comENLV Enlivex Therapeutics Ltd.September 21, 2022 | seekingalpha.comBioCryst Gets FDA Orphan Status for BCX9250 in Fibrodysplasia Ossificans ProgressivaAugust 31, 2022 | marketwatch.comBioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease CandidateAugust 31, 2022 | msn.comAro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe DiseaseAugust 12, 2022 | finance.yahoo.comBioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call TranscriptAugust 11, 2022 | seekingalpha.comBiosight Granted Orphan Drug Designation from the FDA for Aspacytarabine for the Treatment of Myelodysplastic SyndromesAugust 1, 2022 | finance.yahoo.comCitius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell LymphomaJuly 12, 2022 | markets.businessinsider.comGlobal Orphan Drugs Global Market Report (2022 to 2031) - Featuring Amgen, Biogen, Novartis and Novo Nordisk Among Others - ResearchAndMarkets.comJuly 8, 2022 | apnews.comAPyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDAJuly 7, 2022 | apnews.comAAura Biosciences Gets Fast Track Designation for AU-011 Bladder Cancer TreatmentJune 30, 2022 | marketwatch.com Get Bioblast Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORPN Media Mentions By Week ORPN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORPN News Sentiment▼0.000.72▲Average Medical News Sentiment ORPN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORPN Articles This Week▼02▲ORPN Articles Average Week Get the Latest News and Ratings for ORPN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Bioblast Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Vaccinex News Today Evofem Biosciences News Today Petros Pharmaceuticals News Today Bio-Path News Today Hepion Pharmaceuticals News Today Trevena News Today Vincerx Pharma News Today Syros Pharmaceuticals News Today Virpax Pharmaceuticals News Today Neonc Technologies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORPN) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioblast Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
